Aura Biosciences completed a public offering raising approximately $299.4 million by selling over 46 million shares of common stock and pre-funded warrants. The offering included the full exercise of underwriters' option to purchase additional shares, priced at $6.00 per share. This capital raise supports Aura's development of precision therapies for solid tumors, including their lead candidate, bel-sar (AU-011), in late-stage trials for ocular melanoma and early development for other cancers. The funds will help advance clinical programs and company growth.
Resonate introduced Signature Segmentation, a new service that transforms first-party customer data into distinct audience groups based on motivations rather than just demographics or past behavior. This approach helps brands understand why customers...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
SLC Digital has expanded its Board of Directors and Strategic Advisory Board as it enters a new phase of commercial growth following a strategic investment led by C7, a 7RIDGE subsidiary. The new leadership includes experienced executives from techno...
Investec Bank plc, acting as a joint broker for Gamma Communications Plc, disclosed a public dealing on July 27, 2026, involving the purchase and sale of 96,419 ordinary shares of Gamma Communications. The transactions were executed at prices ranging...
Investec Bank plc, acting as advisor and broker for Gooch & Housego plc, disclosed public dealings under the Takeover Code on July 27, 2026. The bank purchased 8,073 ordinary shares at prices between 1220 and 1230 pence and sold 6,000 shares at price...
